One Network, Many Nodes: How Japan’s Drug Discovery Hubs Can Compete Globally in the Next Decade

Japan’s drug discovery scene has no shortage of ideas—or infrastructure. What it has lacked, historically, is a unified way to turn dispersed excellence into investable, globally competitive companies. The problem is structural: multiple regional hubs, each with distinct strengths, often move in parallel rather than in concert. The solution taking shape is a national mesh—shared standards, shared data, and shared market access—knit together by deliberate cross-hub collaboration and two-way bridges to the U.S. and Europe.

That vision anchored the “Cross-Talk Among Drug Discovery Hubs” session during BioJapan, moderated by LabCentral CEO Dr. Maggie O’Toole, with leaders from Kashiwanoha Campus (National Cancer Center Hospital East), Shonan Health Innovation Park, Nakanoshima Cross in Osaka, and the Kobe Biomedical Innovation Cluster. Together they offered a pragmatic blueprint: connect pipelines, harmonize to FDA/PMDA expectations from day one, and use soft-landing programs to make global capital and partners routine rather than rare.

During the discussion, speakers emphasized the importance of cross-hub collaboration, regulatory alignment, and shared data systems — outlining how Japan’s regional drug discovery hubs can connect academia, pharma, and infrastructure into a unified, globally competitive biotech network. Image: GeneOnline

Why Hubs Matter—and Why Japan’s Are Different

Japan’s hubs were built around science first, companies second. That is an asset if the pieces interlock. Dr. Toshihiko Doi of the National Cancer Center described how oncology trials—long a Japanese strength for quality—are now expanding in ambition as first-in-human and first-in-class studies increase. “The quality of trials in Japan has been well regarded,” he said. “Speed and cost have lagged, but our oncology first-in-human capability is clearly rising.” He pointed to SCRUM-Japan’s multimodal genomic database—now approaching 100,000 cases—as the undercarriage for faster study design and enrollment. “When basic discovery is tethered to a living clinical database, the pathway to a credible FIH becomes visible.”

That clinical backbone is one reason regional facilities are deepening links with industry earlier. “Our facility has leaned into academia-originated FIH,” Doi noted. “It’s becoming a defining feature.”

Dr. Toshihiko Doi (featured) highlighted Japan’s growing first-in-human oncology capabilities and the role of clinical–genomic integration in accelerating global drug development. Image: GeneOnline

Shonan iPark’s “Under One Roof” Model—and a U.S. On-Ramp

At Shonan Health Innovation Park (iPark), Dr. Toshio Fujimoto described a campus designed to feel less like a landlord and more like a magnet. “From the beginning we wanted two things,” he said. “A place researchers admire—and a place where science actually flows.” The numbers suggest it’s working: roughly 130 tenant organizations (about 40% startups), 2,600–2,800 people on site, and last year alone two IPOs, two M&A exits, and four startup-led clinical trials launched from the campus.

Crucially, iPark is opening outward. Fujimoto flagged a November Boston Health Innovation event and a new education-and-matching partnership with LabCentral. O’Toole added details: a three-month Cambridge, MA soft-landing program that embeds Japanese teams with U.S. scientists, pharma BD, and investors. “We hear the same thing from founders,” she said. “Having an address in Cambridge still matters for getting meetings. We’re lowering that threshold—and we want it to be two-way, with U.S. scientists coming into Japan as well.”

Osaka’s Nakanoshima Cross: R&D, Care, and Regulators in One Loop

Prof. Yoshiki Sawa outlined Nakanoshima Cross, a year-old complex in central Osaka that splices an R&D tower and a clinical tower, with PMDA engagement built into the operating model. “One building, two halves—research and medical—so the handoff from bench to bedside is literal,” he said. “We meet regulatory science head-on to de-risk translation.” Sawa’s long view is frank: “Japan has many ‘diamonds’ that haven’t been polished. We’re building an ecosystem that starts global, not local—FDA-level thinking from day one, so Japan is easy to include in global trials instead of being an afterthought.”

That mindset is already shaping trial design—global first, with Japan as an early participant—so duplication of Japan-first and then U.S. cycles doesn’t sap time and capital. “If you proceed at FDA level from the start,” Sawa said, “PMDA and European involvement follow more smoothly.”

Kobe’s Scale Play: Digital, Devices, and Supercomputing

Kozo Mori of the Kobe Biomedical Innovation Cluster emphasized capabilities that complement pure therapeutics: world-class supercomputing assets, robotics, and advanced manufacturing. From a Japanese-made surgical robot to iPS cell–assisted transplant support, Kobe has leaned into digital and devices as force multipliers for clinical development. The message to drug developers is simple: bring the molecule, but also bring your modeling and enabling tech questions. “The ecosystem is strongest,” Mori observed, “when we treat compute, devices, and therapeutics as one continuum.”

Collaboration, Not Sectionalism: A National Mesh

If there was a single refrain, it was the end of hub sectionalism. “There’s no reason we can’t connect,” Sawa said. “If the four of us work together, we can move quickly.” Fujimoto agreed, noting a pre-panel huddle where the group sketched a practical division of labor: upstream academic seeding and early venture formation at university-anchored nodes; scaling and investor-facing maturation at iPark; clinical validation and regulatory integration at Nakanoshima; and digital/industrial muscle out of Kobe. O’Toole’s readout was blunt: the alignment is there, and investors notice when regions sing from the same score.

Global from Day One: FDA as a Design Constraint, Not a Destination

Much of the conversation circled back to the same leverage point: regulatory convergence. If Japanese programs design to FDA and PMDA simultaneously, sponsors avoid serial development and unlock earlier ex-Japan participation. “Think global trials from the beginning,” Sawa urged. “It changes who shows up to mentor, to invest, and to partner.” Doi seconded the view: oncology trials that start with global endpoints and biomarker strategies are easier to enroll and easier to sell to partners.

Here, the LabCentral–iPark soft-landing program is more than optics. It creates muscle memory—scientific seminars with U.S. KOLs, BD sprints with big pharma, and realistic term-sheet expectations that match U.S. market norms. “We want this to be a two-way street,” O’Toole said. “Cross-pollination is what reduces risk for both capital and science.”

Capital: Reverse Gravity and the Case for Speed

Capital remains the hardest bottleneck. The panel’s workaround is to reverse the gravity: attract experienced overseas mentors and VCs first, then let domestic capital follow the signal. “If overseas investors are already at the table, Japanese investors engage more quickly,” Sawa noted. That view dovetails with government momentum—support for startups, translational programs, and CDMO manufacturing—that can shorten the distance from prototype to product if industry and hubs coordinate.

Speed, they stressed, is not the enemy of quality; it’s the outcome of clarity. “When your trial is FDA-ready, your diligence is PMDA-ready, and your endpoints are globally intelligible,” Doi said, “every other step becomes faster.”

Ten Years Out: A Japanese Ecosystem That Acts Like One

What does success look like by 2035? Not one mega-cluster, but a connected few—each with a sharp edge, all interoperable. Fujimoto referenced the U.S. reality: even in a vast market, true biotech superclusters number three or four. Japan, by contrast, has promising research spread across many campuses. The opportunity is to bind them, not flatten them. “Different hubs can lead different fields,” he said. “What matters is activating the whole as one market-facing system.”

Mori expects the next decade’s maturity to come from process and infrastructure as much as science. Sawa framed it as timing: government support (“heaven”), regional assets (“earth”), and entrepreneurial talent (“people”) are aligning. “If we connect those,” he said, “we will create an ecosystem that consistently produces unicorns—and medicines that matter.”

O’Toole closed on a similar note. “There are many seeds—and plenty of diamonds ready to be polished,” she said. “What’s promising is not just the quality of the science, but the willingness to collaborate across hubs. That’s what the market responds to.”

Building Better Science: Potential Strategies for Researchers Turning Innovation into Real-World Impact

For founders, PIs, and BD leads who want to plug into this national mesh, the panel’s through-line can be distilled to a workable sequence—no buzzwords required.

Design global from day one. Choose endpoints, biomarkers, and data packages that meet FDA and PMDA needs simultaneously; plan global first-in-human where feasible, with Japan as an early enrolling region. This avoids serial development—and doubles your pool of mentors and capital.

Pick the right hub for the right phase. Incubate near your academic engine; graduate to iPark for scale, investors, and pharma proximity; validate at Nakanoshima where care teams and regulators sit next door; tap Kobe for compute, devices, and industrial partners. The handoffs are the strategy.

Make U.S. access routine, not exceptional. Use the LabCentral–iPark soft-landing to get an address in Cambridge, sit with U.S. KOLs, and reality-check term sheets. Bring those lessons back—then host the reverse flow by inviting U.S. teams to your site.

Anchor on data credibility. Borrow best practices from GLP/GCP CROs early—traceable materials, reproducible protocols, harmonized documentation. The earlier your data speak a common regulatory language, the fewer “translation taxes” you pay later.

Collapse time with common tooling. Shared clinical databases (e.g., SCRUM-Japan), shared protocol templates, and shared regulatory playbooks shorten every cycle. Treat these as public goods across hubs.

Signal fast decision-making. Investors price speed. Map your governance to hit CDA, diligence, and TS milestones in weeks, not quarters. The hubs can help; use their cadence.

Recruit globally—and visibly. Bring in mentors and interim execs with FDA, BD, and IPO/M&A muscle. When experienced names appear on your org chart, partners stop asking if you’re “ready.”

None of this guarantees an easy road. But taken together, it replaces the go-it-alone model with a network that compounds advantages: better trial design, more credible data, faster partner engagement, and a clearer line of sight to global markets. Japan doesn’t need to become Boston or San Diego. It needs to behave like one system—and, judging by this cross-talk, that system is finally coming into view.

Related posts:

From Lab Bench to Global Market: A Practical Playbook for Japan’s Biotech Startups Decoding the Global Biopharma Network: How Data-Driven Partnering Is Redefining Japan’s Next Move Rebuilding the Bio-Economy: How Global Collaboration and Green Science Can Redefine Japan’s Manufacturing Future Bridging the Divide: How CRO Partnerships Can Turn Academic Discoveries into Real Drugs

Author

Bernice Lottering